Melanoma vaccines and viral-based immunotherapies: a special focus issue from .
作者信息
Dillman Robert O, Dennis-Beron Sebastian
机构信息
AiVita Biomedical, 18301 Von Karman Avenue, Suite 130, Irvine, CA 92612, USA.
Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK.
出版信息
Melanoma Manag. 2016 Dec;3(4):245-246. doi: 10.2217/mmt-2016-0030. Epub 2016 Nov 30.
Abstract
摘要
相似文献
1
Melanoma vaccines and viral-based immunotherapies: a special focus issue from .
Melanoma Manag. 2016 Dec;3(4):245-246. doi: 10.2217/mmt-2016-0030. Epub 2016 Nov 30.
2
Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.
Nanomedicine. 2021 Oct;37:102443. doi: 10.1016/j.nano.2021.102443. Epub 2021 Jul 23.
3
Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
J Immunother Cancer. 2016 Dec 20;4:96. doi: 10.1186/s40425-016-0189-y. eCollection 2016.
4
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Cancer Immunol Immunother. 2020 Jan;69(1):135-145. doi: 10.1007/s00262-019-02448-z. Epub 2019 Dec 5.
5
Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies.
J Control Release. 2023 Jan;353:423-433. doi: 10.1016/j.jconrel.2022.11.053. Epub 2022 Dec 7.
6
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.
Curr Opin Oncol. 2023 Mar 1;35(2):94-99. doi: 10.1097/CCO.0000000000000923. Epub 2023 Jan 11.
7
Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy.
Cancer Lett. 2023 Jun 1;563:216190. doi: 10.1016/j.canlet.2023.216190. Epub 2023 Apr 14.
8
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23662-23670. doi: 10.1073/pnas.1906026116. Epub 2019 Nov 4.
9
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer.
Front Immunol. 2023 Jan 25;14:1104860. doi: 10.3389/fimmu.2023.1104860. eCollection 2023.
10
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Cancer Discov. 2018 Nov;8(11):1366-1375. doi: 10.1158/2159-8290.CD-17-1418. Epub 2018 Sep 12.
引用本文的文献
1
Welcome to the fourth volume of and a look back at 2016.
Melanoma Manag. 2017 Mar;4(1):1-3. doi: 10.2217/mmt-2016-0033. Epub 2017 Mar 3.
本文引用的文献
1
Dendritic cell vaccines for melanoma: past, present and future.
Melanoma Manag. 2016 Dec;3(4):273-289. doi: 10.2217/mmt-2016-0014. Epub 2016 Nov 29.
2
Talimogene laherparepvec: overview, combination therapy and current practices.
Melanoma Manag. 2016 Dec;3(4):267-272. doi: 10.2217/mmt-2016-0021. Epub 2016 Sep 15.
3
Advances in the development of intralesional therapies for melanoma.
Melanoma Manag. 2016 Dec;3(4):259-266. doi: 10.2217/mmt-2016-0020. Epub 2016 Nov 29.
4
Current clinical trials for melanoma vaccines: where do we stand?
Melanoma Manag. 2016 Dec;3(4):255-257. doi: 10.2217/mmt-2016-0009. Epub 2016 Nov 30.
5
Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.
Melanoma Manag. 2016 Dec;3(4):251-254. doi: 10.2217/mmt-2016-0016. Epub 2016 Nov 29.
6
The use of dendritic cell vaccinations in melanoma: where are we now?
Melanoma Manag. 2016 Dec;3(4):247-250. doi: 10.2217/mmt-2016-0027. Epub 2016 Nov 29.
Zotero 插件